PDCL

Summary

PDCL (phosducin like, HGNC:8770) is a protein-coding gene on chromosome 9q33.2, encoding Phosducin-like protein (Q13371). Acts as a positive regulator of hedgehog signaling and regulates ciliary function. It is a selective cancer dependency (DepMap: 30.0% of cell lines).

Phosducin-like protein is a putative modulator of heterotrimeric G proteins. The protein shares extensive amino acid sequence homology with phosducin, a phosphoprotein expressed in retina and pineal gland. Both phosducin-like protein and phosphoducin have been shown to regulate G-protein signaling by binding to the beta-gamma subunits of G proteins.

Source: NCBI Gene 5082 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 46 total
• Cancer dependency (DepMap): dependent in 30.0% of screened cell lines
• MANE Select transcript: NM_005388

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8770
Approved symbol	PDCL
Name	phosducin like
Location	9q33.2
Locus type	gene with protein product
Status	Approved
Aliases	PhLP, DKFZp564M1863
Ensembl gene	ENSG00000136940
Ensembl biotype	protein_coding
OMIM	604421
Entrez	5082

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000259467, ENST00000394285, ENST00000436632, ENST00000935271, ENST00000935272, ENST00000935273, ENST00000943131

RefSeq mRNA: 1 — MANE Select: NM_005388 NM_005388

CCDS: CCDS6845

Canonical transcript exons

ENST00000259467 — 4 exons

Exon	Start	End
ENSE00000806541	122826616	122826792
ENSE00000927037	122823016	122823197
ENSE00001091240	122818097	122820636
ENSE00001517952	122828471	122828588

Expression profiles

Bgee: expression breadth ubiquitous, 281 present calls, max score 97.64.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.3028 / max 214.7140, expressed in 1817 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
102395	22.3708	1814
102394	0.9321	648

Top tissues by expression

296 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	97.64	gold quality
endothelial cell	CL:0000115	96.70	silver quality
visceral pleura	UBERON:0002401	94.18	gold quality
oocyte	CL:0000023	93.45	gold quality
parietal pleura	UBERON:0002400	92.86	gold quality
tibia	UBERON:0000979	92.73	gold quality
pleura	UBERON:0000977	92.46	gold quality
calcaneal tendon	UBERON:0003701	92.32	gold quality
secondary oocyte	CL:0000655	91.89	gold quality
cervix squamous epithelium	UBERON:0006922	91.63	silver quality
germinal epithelium of ovary	UBERON:0001304	91.04	gold quality
epithelium of nasopharynx	UBERON:0001951	90.05	gold quality
nasopharynx	UBERON:0001728	90.04	gold quality
tendon	UBERON:0000043	89.58	gold quality
oral cavity	UBERON:0000167	89.42	gold quality
ganglionic eminence	UBERON:0004023	89.09	gold quality
trabecular bone tissue	UBERON:0002483	88.33	gold quality
stromal cell of endometrium	CL:0002255	88.15	gold quality
embryo	UBERON:0000922	88.06	gold quality
periodontal ligament	UBERON:0008266	88.02	gold quality
pigmented layer of retina	UBERON:0001782	87.86	gold quality
retina	UBERON:0000966	87.83	gold quality
superficial temporal artery	UBERON:0001614	87.71	gold quality
seminal vesicle	UBERON:0000998	87.66	gold quality
cauda epididymis	UBERON:0004360	87.66	gold quality
adult organism	UBERON:0007023	87.58	gold quality
cortical plate	UBERON:0005343	87.49	gold quality
gingival epithelium	UBERON:0001949	87.48	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.43	gold quality
choroid plexus epithelium	UBERON:0003911	87.09	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.90

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

80 targeting PDCL, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-10523-5P	99.91	69.22	2038
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-944	99.82	70.85	3042
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-4517	99.76	69.19	1867
HSA-MIR-92A-2-5P	99.75	67.01	2164

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 30.0% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 7)

• physiological control of G-protein regulation by PhLP seems to involve phosphorylation by CK2 and alternative splicing of the regulator (PMID:12466282)
• the strong inhibitory action of PhLP(S) on Gbetagamma signaling is the result of a previously unrecognized mechanism of Gbetagamma-regulation, inhibition of Gbetagamma-folding by interference with TCP-1alpha (PMID:15745879)
• PhLP phosphorylation permits the release of a PhLP x Gbeta intermediate from cytosolic chaperonin complex, allowing Ggamma to associate with Gbeta in this intermediate complex. (PMID:16717095)
• cytosolic chaperonin complex-dependent mechanism exists for Gbeta5-RGS7 assembly that utilizes the co-chaperone activity of PhLP1 in a unique way (PMID:19376773)
• PhLP-M1-G149, a Gbetagamma-interacting construct derived from phosducin-like protein 1 (PhLP) is a differential inhibitor of Gbetagamma (PMID:19403526)
• evidence of a generic mechanism, whereby the splicing of the PhLP gene could potentially and efficiently regulate the cellular levels of heterotrimeric G proteins. (PMID:23888055)
• PhLP1 binding stabilizes the Gbeta fold, disrupting interactions with CCT and releasing a PhLP1-Gbeta dimer for assembly with Ggamma. (PMID:25675501)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	pdcl	ENSDARG00000009480
mus_musculus	Pdcl	ENSMUSG00000009030
rattus_norvegicus	Pdcl	ENSRNOG00000008484
rattus_norvegicus	AABR07051787.1	ENSRNOG00000059243
drosophila_melanogaster	CG7650	FBGN0036519
caenorhabditis_elegans		WBGENE00003142

Paralogs (4): TXNDC9 (ENSG00000115514), PDCL3 (ENSG00000115539), PDC (ENSG00000116703), PDCL2 (ENSG00000163440)

Protein

Protein identifiers

Phosducin-like protein — Q13371 (reviewed: Q13371)

All UniProt accessions (3): Q13371, H0Y3M0, H0Y5D3

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a positive regulator of hedgehog signaling and regulates ciliary function. Functions as a co-chaperone for CCT in the assembly of heterotrimeric G protein complexes, facilitates the assembly of both Gbeta-Ggamma and RGS-Gbeta5 heterodimers. Acts as a negative regulator of heterotrimeric G proteins assembly by trapping the preloaded G beta subunits inside the CCT chaperonin.

Subunit / interactions. Forms a complex with the beta and gamma subunits of the GTP-binding protein, transducin. Interacts with the CCT chaperonin complex.

Subcellular location. Cell projection. Cilium.

Miscellaneous. Expressed ubiquitously, highest levels are found in neural tissues amounting to 10% of total PDCL mRNA.

Similarity. Belongs to the phosducin family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q13371-1	1	yes
Q13371-2	2, PhLPs

RefSeq proteins (1): NP_005379* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001200	Phosducin	Family
IPR023196	Phosducin_N_dom_sf	Homologous_superfamily
IPR024253	Phosducin_thioredoxin-like_dom	Domain
IPR036249	Thioredoxin-like_sf	Homologous_superfamily
IPR051499	Phosducin-like_reg	Family

Pfam: PF02114

UniProt features (34 total): helix 9, strand 8, modified residue 6, sequence conflict 2, turn 2, initiator methionine 1, chain 1, splice variant 1, sequence variant 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

19 structures.

PDB	Method	Resolution (Å)
8SH9	ELECTRON MICROSCOPY	2.7
8SHG	ELECTRON MICROSCOPY	2.8
8SGC	ELECTRON MICROSCOPY	2.9
8SHQ	ELECTRON MICROSCOPY	2.9
9NOQ	ELECTRON MICROSCOPY	2.9
9NRH	ELECTRON MICROSCOPY	2.9
8SG8	ELECTRON MICROSCOPY	3
8SHA	ELECTRON MICROSCOPY	3
8SHF	ELECTRON MICROSCOPY	3
8SHL	ELECTRON MICROSCOPY	3
8SHO	ELECTRON MICROSCOPY	3
8SHP	ELECTRON MICROSCOPY	3
8SHT	ELECTRON MICROSCOPY	3
9NPW	ELECTRON MICROSCOPY	3
9NOP	ELECTRON MICROSCOPY	3.1
9NQ6	ELECTRON MICROSCOPY	3.1
9NRF	ELECTRON MICROSCOPY	3.1
9NOC	ELECTRON MICROSCOPY	3.17
8SFF	ELECTRON MICROSCOPY	3.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13371-F1	76.66	0.40

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 296, 2, 20, 25, 226, 293

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6814122	Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding

MSigDB gene sets: 132 (showing top): WHITEHURST_PACLITAXEL_SENSITIVITY, TTTGTAG_MIR520D, GCM_ZNF198, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, SHEPARD_BMYB_MORPHOLINO_DN, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_SENSORY_PERCEPTION_OF_LIGHT_STIMULUS, GOBP_REGULATION_OF_SMOOTHENED_SIGNALING_PATHWAY, DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP, MORF_EPHA7, BENPORATH_NOS_TARGETS, GOBP_SENSORY_PERCEPTION, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, GOBP_SMOOTHENED_SIGNALING_PATHWAY, GOBP_CELL_PROJECTION_ORGANIZATION

GO Biological Process (6): signal transduction (GO:0007165), visual perception (GO:0007601), regulation of G protein-coupled receptor signaling pathway (GO:0008277), cell projection organization (GO:0030030), positive regulation of smoothened signaling pathway (GO:0045880), heterotrimeric G-protein complex assembly (GO:1902605)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): cytoplasm (GO:0005737), cytosol (GO:0005829), cilium (GO:0005929), cell projection (GO:0042995)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Chaperonin-mediated protein folding	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
sensory perception of light stimulus	1
G protein-coupled receptor signaling pathway	1
regulation of signal transduction	1
cellular component organization	1
smoothened signaling pathway	1
regulation of smoothened signaling pathway	1
positive regulation of signal transduction	1
protein-containing complex assembly	1
binding	1
intracellular anatomical structure	1
cytoplasm	1
intraciliary transport particle	1
membrane-bounded organelle	1
plasma membrane bounded cell projection	1

Protein interactions and networks

STRING

1090 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PDCL	GHITM	Q9H3K2	771
PDCL	SUCLG2	Q96I99	735
PDCL	PFN3	P60673	716
PDCL	PFN4	Q8NHR9	716
PDCL	PEDS1	A5PLL7	714
PDCL	GNGT1	P63211	688
PDCL	PFN1	P07737	669
PDCL	GNB1	P04697	662
PDCL	SLC26A5	P58743	580
PDCL	COPS7A	Q9UBW8	580
PDCL	FCER2	P06734	542
PDCL	DNAJC14	Q6Y2X3	522
PDCL	SCP2	P22307	480
PDCL	TMEM45A	Q9NWC5	480
PDCL	ENPP3	O14638	479

IntAct

158 interactions, top by confidence:

A	B	Type	Score
PSMC5	PDCL	psi-mi:“MI:0915”(physical association)	0.920
PDCL	PSMC5	psi-mi:“MI:0915”(physical association)	0.920
CCT3	PDCL	psi-mi:“MI:0915”(physical association)	0.800
PSMC5	PSMD11	psi-mi:“MI:0914”(association)	0.730
CCT2	TXNDC9	psi-mi:“MI:0914”(association)	0.730
HDAC1	ZNF609	psi-mi:“MI:0914”(association)	0.730
CCT2	PPP6C	psi-mi:“MI:0914”(association)	0.640
PDCL3	PEX7	psi-mi:“MI:0914”(association)	0.640
GNB1	GNG7	psi-mi:“MI:0914”(association)	0.640
CCT3	TXNDC9	psi-mi:“MI:0914”(association)	0.640
CCT5	TXNDC9	psi-mi:“MI:0914”(association)	0.640
CCT7	TXNDC9	psi-mi:“MI:0914”(association)	0.640
DCAF12L2	CETN3	psi-mi:“MI:0914”(association)	0.640
GNG8	GNB5	psi-mi:“MI:0914”(association)	0.640
GNG5	GNB5	psi-mi:“MI:0914”(association)	0.620
PDCL	MRPL11	psi-mi:“MI:0915”(physical association)	0.560
PDCL	ATN1	psi-mi:“MI:0915”(physical association)	0.560
KLK6	PDCL	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (214): PSMC5 (Two-hybrid), PDCL (Affinity Capture-MS), PDCL (Affinity Capture-MS), PDCL (Affinity Capture-MS), PDCL (Affinity Capture-MS), PDCL (Affinity Capture-MS), PDCL (Affinity Capture-MS), PDCL (Affinity Capture-MS), PDCL (Affinity Capture-MS), PDCL (Affinity Capture-MS), PDCL (Affinity Capture-MS), PSMC5 (Two-hybrid), PDCL (Proximity Label-MS), PDCL (Proximity Label-MS), PDCL (Proximity Label-MS)

ESM2 similar proteins: A0JM23, A5PMF7, B8JKF4, F4JZJ2, O23052, O60502, O77560, P0CF65, P0CI65, P19632, P20941, P20942, P41686, Q008S8, Q0P564, Q13371, Q2HJA9, Q2TBM9, Q3U213, Q568B8, Q58CZ2, Q5FVM7, Q5R7K4, Q5RCM7, Q5SNQ7, Q5ZKZ4, Q63737, Q68EV9, Q692V3, Q6AZT7, Q6P3V7, Q6P5D8, Q75BD8, Q80TN4, Q8BHD8, Q8S8L9, Q8VC33, Q8VIJ5, Q8VZQ0, Q94HV8

Diamond homologs: O77560, P19632, P20941, P20942, P41686, Q13371, Q2HJA9, Q63737, Q9DBX2, Q9QW08, Q9VUR7, Q9XS39, Q0VCW8, Q4KLJ8, Q5RB77, Q6P268, Q71A38, Q71A39, Q8BVF2, Q9H2J4, Q9Y7L1, Q8MR62, O14530, Q12017, Q32LN3, Q71A37, Q78Y63, Q8K581, Q8N4E4, Q9CQ79, O64628

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
CSNK2A1	up-regulates	PDCL	phosphorylation
CSNK2A1	unknown	PDCL	phosphorylation
GRK2	“down-regulates activity”	PDCL	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 125 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Prostacyclin signalling through prostacyclin receptor	14	109.3×	3e-25
G beta:gamma signalling through BTK	13	107.1×	2e-23
G beta:gamma signalling through PLC beta	13	96.4×	8e-23
G beta:gamma signalling through CDC42	13	96.4×	8e-23
Presynaptic function of Kainate receptors	13	91.8×	2e-22
ADP signalling through P2Y purinoceptor 12	14	90.3×	1e-23
G-protein activation	14	86.5×	2e-23
Thromboxane signalling through TP receptor	14	86.5×	2e-23

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of telomere maintenance via telomerase	10	70.5×	2e-14
binding of sperm to zona pellucida	7	28.4×	5e-07
protein folding	15	14.9×	1e-11
protein stabilization	15	9.7×	6e-09
G protein-coupled receptor signaling pathway	15	5.2×	2e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

46 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	40
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

857 predictions. Top by Δscore:

Variant	Effect	Δscore
9:122823012:TTA:T	donor_loss	1.0000
9:122823013:TACC:T	donor_loss	1.0000
9:122823014:A:T	donor_loss	1.0000
9:122823015:C:CA	donor_loss	1.0000
9:122826611:AGTAC:A	donor_gain	1.0000
9:122826614:ACCTG:A	donor_loss	1.0000
9:122826788:GGTGT:G	acceptor_gain	1.0000
9:122826789:GTGT:G	acceptor_gain	1.0000
9:122826790:TGT:T	acceptor_gain	1.0000
9:122826791:GT:G	acceptor_gain	1.0000
9:122826792:TCTG:T	acceptor_loss	1.0000
9:122826793:C:CA	acceptor_loss	1.0000
9:122826793:C:CC	acceptor_gain	1.0000
9:122820650:A:T	acceptor_gain	0.9900
9:122823018:T:A	donor_gain	0.9900
9:122823027:T:C	donor_gain	0.9900
9:122823198:C:CA	acceptor_loss	0.9900
9:122823198:C:CC	acceptor_gain	0.9900
9:122823224:C:CT	acceptor_gain	0.9900
9:122826624:A:C	donor_gain	0.9900
9:122828417:C:CA	donor_gain	0.9900
9:122828466:GTTAC:G	donor_loss	0.9900
9:122828467:TTACC:T	donor_loss	0.9900
9:122828468:TAC:T	donor_loss	0.9900
9:122828469:ACC:A	donor_loss	0.9900
9:122828470:C:A	donor_loss	0.9900
9:122828479:G:C	donor_gain	0.9900
9:122820649:C:CT	acceptor_gain	0.9800
9:122823225:A:T	acceptor_gain	0.9800
9:122826614:A:AC	donor_gain	0.9800

AlphaMissense

2031 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:122820560:C:G	R144P	0.999
9:122823170:C:G	R67P	0.999
9:122823176:T:A	D65V	0.999
9:122823189:C:G	G61R	0.999
9:122823190:T:A	K60N	0.999
9:122823190:T:G	K60N	0.999
9:122820188:A:G	L268P	0.998
9:122820281:A:G	L237P	0.998
9:122820290:G:C	P234R	0.998
9:122820290:G:T	P234H	0.998
9:122820307:G:C	F228L	0.998
9:122820307:G:T	F228L	0.998
9:122820308:A:G	F228S	0.998
9:122820309:A:G	F228L	0.998
9:122820569:C:G	R141P	0.998
9:122823160:C:A	K70N	0.998
9:122823160:C:G	K70N	0.998
9:122823163:G:C	F69L	0.998
9:122823163:G:T	F69L	0.998
9:122823165:A:G	F69L	0.998
9:122823176:T:C	D65G	0.998
9:122823176:T:G	D65A	0.998
9:122823194:G:T	P59Q	0.998
9:122823197:C:T	G58D	0.998
9:122820245:A:T	V249D	0.997
9:122820284:A:G	L236P	0.997
9:122820287:G:T	A235D	0.997
9:122820350:A:G	F214S	0.997
9:122820374:G:T	A206D	0.997
9:122820375:C:G	A206P	0.997

dbSNP variants (sampled 300 via entrez): RS1000103836 (9:122818327 A>C), RS1000193961 (9:122830456 T>C), RS1000244984 (9:122818564 T>A), RS1000296201 (9:122824435 G>A), RS1000369487 (9:122827949 T>G), RS1000850464 (9:122820053 C>A,T), RS1000996402 (9:122826322 T>C), RS1001663396 (9:122818063 C>T), RS1001684979 (9:122823477 C>T), RS1002144398 (9:122828807 A>C), RS1002311407 (9:122828972 T>A), RS1003043873 (9:122819194 G>A), RS1003099973 (9:122826565 T>G), RS1003152378 (9:122826266 T>C), RS1003430414 (9:122824823 T>C,G)

Disease associations

OMIM: gene MIM:604421 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001762_547	Obesity-related traits	5.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004338	body weight

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	3
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
bisphenol F	affects cotreatment, increases expression	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
kojic acid	increases expression	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
abrine	decreases expression	1
Bortezomib	increases expression	1
Resveratrol	increases expression, affects cotreatment	1
Temozolomide	increases expression	1
Leflunomide	decreases expression	1
Acetaminophen	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Diuron	decreases expression	1
Emodin	decreases expression	1
Indomethacin	affects cotreatment, increases expression	1
Lead	increases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Smoke	increases abundance, increases expression	1
Thiram	increases expression	1
Urethane	increases expression	1
1-Methyl-3-isobutylxanthine	increases expression, affects cotreatment	1
Copper Sulfate	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.